Information  X 
Enter a valid email address

Genedrive PLC (GDR)

  Print      Mail a friend       Annual reports

Friday 07 December, 2018

Genedrive PLC

2018 Annual Report and AGM Notice

RNS Number : 8662J
Genedrive PLC
07 December 2018
 

For release: 7 December 2018

 

 

2018 Annual Report and AGM Notice

genedrive plc (LSE: GDR), the near patient molecular diagnostics company, gives notice that copies of its 2018 Annual Report and Notice of the 2018 Annual General Meeting have been posted to shareholders. The AGM will be held at 11:00 on 31 December 2018 at the offices of Addleshaw Goddard LLP, Milton Gate, 60 Chiswell Street, London, EC1Y 4AG.

Copies of these documents may be found on the Company's website (www.genedriveplc.com)

- Ends -

For further details please contact:

genedrive plc

+44 (0)161 989 0245

 

David Budd: CEO

 

 

Matthew Fowler: CFO

 

 

 

 

 

Peel Hunt LLP

 

 

James Steel

+44 (0)207 418 8900

 

Oliver Jackson

 

 

 

 

 

Stanford Capital Partners Limited

Patrick Claridge

+44 (0)203 815 8880

+44 (0)203 815 8880

John Howes

 

 

 

 

 

Consilium Strategic Communications

+44 (0)203 709 5700

 

Chris Gardner

[email protected]

 

Matthew Neal

 

 

Laura Thornton

 

 

 

Notes to Editors

About genedrive plc

genedrive plc is a molecular diagnostics company developing and commercialising a low cost, rapid, versatile, simple to use and robust point of need molecular diagnostics platform for the diagnosis of infectious diseases and for use in patient stratification (genotyping), pathogen detection and other indications. The Genedrive® HCV-ID test has received CE-IVD Certification and has been launched in Africa and Asia Pacific. genedrive has distribution agreements with subsidiaries of Sysmex Corporation for the distribution of the Genedrive® platform in the EMEA and SE Asia (ex-India), and with ARKRAY Healthcare pvt Ltd for the distribution of the Genedrive® HCV-ID Kit and Genedrive® platform in India. Further details can be found at: www.genedriveplc.com and www.genedrive.com. The Company also has tests in development for tuberculosis (mTB) and Antibiotic Induced Hearing Loss (AIHL).

 


This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact [email protected] or visit www.rns.com.
 
END
 
 
MSCBUBDDDGGBGIR

a d v e r t i s e m e n t